4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18. November 2024 08:00 ET
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and...
4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18. November 2024 02:00 ET
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and...
4BIO Capital Becomes First UK Venture Fund Certified by Japan's AMED
14. November 2024 08:00 ET
|
4Bio Capital
Press Release 4BIO Capital Becomes First UK Venture Fund Certified by Japan's AMED 4BIO Capital named as the first and only UK-based venture fund to be accredited by the Japan Agency for Medical...
4BIO Capital Becomes First UK Venture Fund Certified by Japan's AMED
14. November 2024 03:00 ET
|
4Bio Capital
Press Release 4BIO Capital Becomes First UK Venture Fund Certified by Japan's AMED 4BIO Capital named as the first and only UK-based venture fund to be accredited by the Japan Agency for Medical...
4BIO Capital Strengthens Investment Team
04. November 2024 08:00 ET
|
4Bio Capital
Press Release LONDON, 4 November 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced and emerging therapies sector, announces today the...
4BIO Capital Strengthens Investment Team
04. November 2024 03:00 ET
|
4Bio Capital
Press Release LONDON, 4 November 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced and emerging therapies sector, announces today the...
4BIO Capital leads oversubscribed $28.4 million Series A financing of March Biosciences
23. Oktober 2024 08:05 ET
|
4Bio Capital
March Bio is rapidly advancing its innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy, MB-105, in development for the treatment of relapsed and refractory CD5 positive T-cell...
4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity
09. April 2024 08:05 ET
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity Long-Term Partnership Agreed with Beacon Therapeutics for Clinical and Commercial AAV...
4BIO Capital Strengthens Advisory Board and Investment Team
11. März 2024 10:00 ET
|
4Bio Capital
Press Release 4BIO Capital Strengthens Advisory Board and Investment Team Industry veteran and former CEO of Vifor Pharma Abbas Hussain and world leading vectorology expert and LogicBio...
Development Bank of Japan invests in 4BIO Capital’s Ventures III fund
04. Januar 2024 07:00 ET
|
4Bio Capital
Press Release Development Bank of Japan invests in 4BIO Capital’s Ventures III fund 4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in advanced...